News und Analysen
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: Nemetschek SE: Successful Start to the Year in Q1 2023 with Continued Strong Growth in Subscriptions and SaaS
EQS-News: Nemetschek SE: Successful Start to the Year in Q1 2023 with Continued Strong Growth in Subscriptions and SaaS
EQS-Adhoc: VARTA AG exceeds forecast for adjusted EBITDA in 2022
EQS-Adhoc: VARTA AG exceeds forecast for adjusted EBITDA in 2022
EQS-News: CANCOM: K-Businesscom becomes part of the CANCOM Group
EQS-News: CANCOM: K-Businesscom becomes part of the CANCOM Group
EQS-Adhoc: CANCOM SE: CANCOM SE takes over KBC Beteiligungs GmbH
EQS-Adhoc: CANCOM SE: CANCOM SE takes over KBC Beteiligungs GmbH
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
EQS-News: Evotec SE provides update on cyber attack
EQS-News: Evotec SE provides update on cyber attack
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle
EQS-News: Supervisory Board appoints Claudia Schmitt as CFO of Siltronic AG to succeed Rainer Irle
EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.
EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.
EQS-Adhoc: United Internet with successful fiscal year 2022
EQS-Adhoc: United Internet with successful fiscal year 2022
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept
EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance
EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: Nemetschek SE lays decisive foundations for future dynamic growth after successful 2022 financial year
EQS-News: Nemetschek SE lays decisive foundations for future dynamic growth after successful 2022 financial year
EQS-Adhoc: VARTA AG: VARTA AG successfully completes capital increase with gross proceeds of approximately 51 million euros
EQS-Adhoc: VARTA AG: VARTA AG successfully completes capital increase with gross proceeds of approximately 51 million euros